URSO 250® (ursodiol, 250 mg) and URSO Forte™ (ursodiol, 500 mg) are available as film-coated tablets for oral administration. Ursodiol (ursodeoxycholic acid, UDCA) is a naturally occurring bile acid found in small quantities in normal human bile and in larger quantities in the biles of certain species of bears. It is a bitter-tasting white powder consisting of crystalline particles freely soluble in ethanol and glacial acetic acid, slightly soluble in chloroform, sparingly soluble in ether, and practically insoluble in water.
URSO 250® and URSO Forte™ (ursodiol) tablets are indicated for the treatment of patients with primary biliary cirrhosis.
Media Articles Related to Urso (Ursodiol)
Dietary kit reduces baby blues, a precursor to postpartum depression
Source: Depression News From Medical News Today [2017.03.15]
A dietary supplement kit, created to counter mood-altering brain changes linked to depression, virtually eliminated the "baby blues" among women in a new study at Toronto's Centre for Addiction and...
Smoking increases risk of precancerous colorectal lesions in women more than in men
Source: Colorectal Cancer News From Medical News Today [2016.11.07]
Men are more likely to develop colorectal cancer or its precursors than women. A new study conducted by MedUni Vienna shows that known risk factors do not explain this difference between the sexes.
Primary Biliary Cirrhosis Treatment (PBC)
Source: MedicineNet budesonide Specialty [2016.06.07]
Title: Primary Biliary Cirrhosis Treatment (PBC)
Category: Diseases and Conditions
Created: 8/21/2001 12:00:00 AM
Last Editorial Review: 6/7/2016 12:00:00 AM
Primary Biliary Cirrhosis (PBC)
Source: MedicineNet cholestyramine Specialty [2015.11.23]
Title: Primary Biliary Cirrhosis (PBC)
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 11/23/2015 12:00:00 AM
Published Studies Related to Urso (Ursodiol)
[Comparison on the efficacy and safety of biphenyl dimethyl dicarboxylate and
ursodeoxycholic acid in patients with abnormal alanine aminotransferase:
multicenter, double-blinded, randomized, active-controlled clinical trial]. [Article in Korean] 
ursodeoxycholic acid (UDCA) in patients with abnormal ALT... CONCLUSIONS: DDB was not inferior to UDCA for normalizing ALT level. Furthermore
Efficacy and safety of tauroursodeoxycholic acid in the treatment of liver
cirrhosis: a double-blind randomized controlled trial. 
No direct comparison of tauroursodeoxycholic acid (TUDCA) and ursodeoxycholic
acid (UDCA) has yet been carried out in the treatment of liver cirrhosis in
China... However, both
drugs exert no effect on the serum markers for liver fibrosis during 6-month
Oral solubilized ursodeoxycholic acid therapy in amyotrophic lateral sclerosis: a
randomized cross-over trial. 
To evaluate the efficacy and safety of ursodeoxycholic acid (UDCA) with oral
solubilized formula in amyotrophic lateral sclerosis (ALS) patients, patients
with probable or definite ALS were randomized to receive oral solubilized UDCA
(3.5 g/140 mL/day) or placebo for 3 months after a run-in period of 1 month and
switched to receive the other treatment for 3 months after a wash-out period of 1
Colchicine or methotrexate, with ursodiol, are effective after 20 years in a subset of patients with primary biliary cirrhosis. [2011.09]
BACKGROUND & AIMS: The combination of ursodeoxycholic acid (UDCA), colchicine, and methotrexate (MTX) is effective therapy for a subset of patients with primary biliary cirrhosis (PBC) who do not respond to UDCA. However, the durability of the response is unclear. We investigated whether the response to combination therapy was durable... CONCLUSIONS: Treatment with the combination of UDCA and MTX or UDCA and colchicine led to sustained clinical remission in a subset of patients with PBC. The response to the combination of UDCA and MTX appeared to be more durable than to UDCA and colchicine. Copyright (c) 2011 AGA Institute. Published by Elsevier Inc. All rights reserved.
High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. [2011.09]
OBJECTIVES: Some studies have suggested that ursodeoxycholic acid (UDCA) may have a chemopreventive effect on the development of colorectal neoplasia in patients with ulcerative colitis (UC) and primary sclerosing cholangitis (PSC). We examined the effects of high-dose (28-30 mg/kg/day) UDCA on the development of colorectal neoplasia in patients with UC and PSC... CONCLUSIONS: Long-term use of high-dose UDCA is associated with an increased risk of colorectal neoplasia in patients with UC and PSC.